Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts

Krishan Kumar, Simon Wigfield, Harriet E. Gee, Cecilia M. Devlin, Dean Singleton, Ji Liang Li, Francesca Buffa, Melanie Huffman, Anthony L. Sinn, Jayne Silver, Helen Turley, Russell Leek, Adrian L. Harris, Mircea Ivan

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Inhibition of vascular endothelial growth factor increases response rates to chemotherapy and progression-free survival in glioblastoma. However, resistance invariably occurs, prompting the urgent need for identification of synergizing agents. One possible strategy is to understand tumor adaptation to microenvironmental changes induced by antiangiogenic drugs and test agents that exploit this process. We used an in vivo glioblastoma-derived xenograft model of tumor escape in presence of continuous treatment with bevacizumab. U87-MG or U118-MG cells were subcutaneously implanted into either BALB/c SCID or athymic nude mice. Bevacizumab was given by intraperitoneal injection every 3 days (2.5 mg/kg/dose) and/or dichloroacetate (DCA) was administered by oral gavage twice daily (50 mg/kg/dose) when tumor volumes reached 0.3 cm3 and continued until tumors reached approximately 1.5-2.0 cm3. Microarray analysis of resistant U87 tumors revealed coordinated changes at the level of metabolic genes, in particular, a widening gap between glycolysis and mitochondrial respiration. There was a highly significant difference between U87-MG-implanted athymic nude mice 1 week after drug treatment. By 2 weeks of treatment, bevacizumab and DCA together dramatically blocked tumor growth compared to either drug alone. Similar results were seen in athymic nude mice implanted with U118-MG cells. We demonstrate for the first time that reversal of the bevacizumab-induced shift in metabolism using DCA is detrimental to neoplastic growth in vivo. As DCA is viewed as a promising agent targeting tumor metabolism, our data establish the timely proof of concept that combining it with antiangiogenic therapy represents a potent antineoplastic strategy.

Original languageEnglish
Pages (from-to)749-758
Number of pages10
JournalJournal of Molecular Medicine
Volume91
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Heterografts
Nude Mice
Neoplasms
Glioblastoma
Pharmaceutical Preparations
Tumor Escape
Glycolysis
Therapeutics
Microarray Analysis
Growth
Tumor Burden
Intraperitoneal Injections
Antineoplastic Agents
Vascular Endothelial Growth Factor A
Disease-Free Survival
Bevacizumab
Respiration
Drug Therapy
Genes

Keywords

  • Bevacizumab
  • Dichloroacetate
  • Glycolysis
  • Hypoxia
  • Oxidative phosphorylation

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Cite this

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. / Kumar, Krishan; Wigfield, Simon; Gee, Harriet E.; Devlin, Cecilia M.; Singleton, Dean; Li, Ji Liang; Buffa, Francesca; Huffman, Melanie; Sinn, Anthony L.; Silver, Jayne; Turley, Helen; Leek, Russell; Harris, Adrian L.; Ivan, Mircea.

In: Journal of Molecular Medicine, Vol. 91, No. 6, 06.2013, p. 749-758.

Research output: Contribution to journalArticle

Kumar, K, Wigfield, S, Gee, HE, Devlin, CM, Singleton, D, Li, JL, Buffa, F, Huffman, M, Sinn, AL, Silver, J, Turley, H, Leek, R, Harris, AL & Ivan, M 2013, 'Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts', Journal of Molecular Medicine, vol. 91, no. 6, pp. 749-758. https://doi.org/10.1007/s00109-013-0996-2
Kumar, Krishan ; Wigfield, Simon ; Gee, Harriet E. ; Devlin, Cecilia M. ; Singleton, Dean ; Li, Ji Liang ; Buffa, Francesca ; Huffman, Melanie ; Sinn, Anthony L. ; Silver, Jayne ; Turley, Helen ; Leek, Russell ; Harris, Adrian L. ; Ivan, Mircea. / Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. In: Journal of Molecular Medicine. 2013 ; Vol. 91, No. 6. pp. 749-758.
@article{951aa23fa3c74fc28c5bfdecb00fe3f3,
title = "Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts",
abstract = "Inhibition of vascular endothelial growth factor increases response rates to chemotherapy and progression-free survival in glioblastoma. However, resistance invariably occurs, prompting the urgent need for identification of synergizing agents. One possible strategy is to understand tumor adaptation to microenvironmental changes induced by antiangiogenic drugs and test agents that exploit this process. We used an in vivo glioblastoma-derived xenograft model of tumor escape in presence of continuous treatment with bevacizumab. U87-MG or U118-MG cells were subcutaneously implanted into either BALB/c SCID or athymic nude mice. Bevacizumab was given by intraperitoneal injection every 3 days (2.5 mg/kg/dose) and/or dichloroacetate (DCA) was administered by oral gavage twice daily (50 mg/kg/dose) when tumor volumes reached 0.3 cm3 and continued until tumors reached approximately 1.5-2.0 cm3. Microarray analysis of resistant U87 tumors revealed coordinated changes at the level of metabolic genes, in particular, a widening gap between glycolysis and mitochondrial respiration. There was a highly significant difference between U87-MG-implanted athymic nude mice 1 week after drug treatment. By 2 weeks of treatment, bevacizumab and DCA together dramatically blocked tumor growth compared to either drug alone. Similar results were seen in athymic nude mice implanted with U118-MG cells. We demonstrate for the first time that reversal of the bevacizumab-induced shift in metabolism using DCA is detrimental to neoplastic growth in vivo. As DCA is viewed as a promising agent targeting tumor metabolism, our data establish the timely proof of concept that combining it with antiangiogenic therapy represents a potent antineoplastic strategy.",
keywords = "Bevacizumab, Dichloroacetate, Glycolysis, Hypoxia, Oxidative phosphorylation",
author = "Krishan Kumar and Simon Wigfield and Gee, {Harriet E.} and Devlin, {Cecilia M.} and Dean Singleton and Li, {Ji Liang} and Francesca Buffa and Melanie Huffman and Sinn, {Anthony L.} and Jayne Silver and Helen Turley and Russell Leek and Harris, {Adrian L.} and Mircea Ivan",
year = "2013",
month = "6",
doi = "10.1007/s00109-013-0996-2",
language = "English",
volume = "91",
pages = "749--758",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts

AU - Kumar, Krishan

AU - Wigfield, Simon

AU - Gee, Harriet E.

AU - Devlin, Cecilia M.

AU - Singleton, Dean

AU - Li, Ji Liang

AU - Buffa, Francesca

AU - Huffman, Melanie

AU - Sinn, Anthony L.

AU - Silver, Jayne

AU - Turley, Helen

AU - Leek, Russell

AU - Harris, Adrian L.

AU - Ivan, Mircea

PY - 2013/6

Y1 - 2013/6

N2 - Inhibition of vascular endothelial growth factor increases response rates to chemotherapy and progression-free survival in glioblastoma. However, resistance invariably occurs, prompting the urgent need for identification of synergizing agents. One possible strategy is to understand tumor adaptation to microenvironmental changes induced by antiangiogenic drugs and test agents that exploit this process. We used an in vivo glioblastoma-derived xenograft model of tumor escape in presence of continuous treatment with bevacizumab. U87-MG or U118-MG cells were subcutaneously implanted into either BALB/c SCID or athymic nude mice. Bevacizumab was given by intraperitoneal injection every 3 days (2.5 mg/kg/dose) and/or dichloroacetate (DCA) was administered by oral gavage twice daily (50 mg/kg/dose) when tumor volumes reached 0.3 cm3 and continued until tumors reached approximately 1.5-2.0 cm3. Microarray analysis of resistant U87 tumors revealed coordinated changes at the level of metabolic genes, in particular, a widening gap between glycolysis and mitochondrial respiration. There was a highly significant difference between U87-MG-implanted athymic nude mice 1 week after drug treatment. By 2 weeks of treatment, bevacizumab and DCA together dramatically blocked tumor growth compared to either drug alone. Similar results were seen in athymic nude mice implanted with U118-MG cells. We demonstrate for the first time that reversal of the bevacizumab-induced shift in metabolism using DCA is detrimental to neoplastic growth in vivo. As DCA is viewed as a promising agent targeting tumor metabolism, our data establish the timely proof of concept that combining it with antiangiogenic therapy represents a potent antineoplastic strategy.

AB - Inhibition of vascular endothelial growth factor increases response rates to chemotherapy and progression-free survival in glioblastoma. However, resistance invariably occurs, prompting the urgent need for identification of synergizing agents. One possible strategy is to understand tumor adaptation to microenvironmental changes induced by antiangiogenic drugs and test agents that exploit this process. We used an in vivo glioblastoma-derived xenograft model of tumor escape in presence of continuous treatment with bevacizumab. U87-MG or U118-MG cells were subcutaneously implanted into either BALB/c SCID or athymic nude mice. Bevacizumab was given by intraperitoneal injection every 3 days (2.5 mg/kg/dose) and/or dichloroacetate (DCA) was administered by oral gavage twice daily (50 mg/kg/dose) when tumor volumes reached 0.3 cm3 and continued until tumors reached approximately 1.5-2.0 cm3. Microarray analysis of resistant U87 tumors revealed coordinated changes at the level of metabolic genes, in particular, a widening gap between glycolysis and mitochondrial respiration. There was a highly significant difference between U87-MG-implanted athymic nude mice 1 week after drug treatment. By 2 weeks of treatment, bevacizumab and DCA together dramatically blocked tumor growth compared to either drug alone. Similar results were seen in athymic nude mice implanted with U118-MG cells. We demonstrate for the first time that reversal of the bevacizumab-induced shift in metabolism using DCA is detrimental to neoplastic growth in vivo. As DCA is viewed as a promising agent targeting tumor metabolism, our data establish the timely proof of concept that combining it with antiangiogenic therapy represents a potent antineoplastic strategy.

KW - Bevacizumab

KW - Dichloroacetate

KW - Glycolysis

KW - Hypoxia

KW - Oxidative phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=84878620894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878620894&partnerID=8YFLogxK

U2 - 10.1007/s00109-013-0996-2

DO - 10.1007/s00109-013-0996-2

M3 - Article

C2 - 23361368

AN - SCOPUS:84878620894

VL - 91

SP - 749

EP - 758

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 6

ER -